CoreWeave Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy CRWV?
Source: Globenewswire
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against CoreWeave in the U.S. District Court for New Jersey on behalf of investors who purchased securities between March 28, 2025, and December 15, 2025, indicating significant legal risks for the company.
- False Statement Allegations: The lawsuit alleges that CoreWeave and its executives made false and misleading statements, failing to disclose the risks associated with reliance on a single third-party data center supplier, which could materially impact the company's revenue and investor confidence.
- Investor Rights Protection: Investors must apply by March 13, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the potential implications of the case on investor rights and interests.
- Legal Consultation Channels: Bragar Eagel & Squire offers no-cost legal consultations, encouraging affected investors to contact attorneys for more information, demonstrating a commitment to protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRWV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRWV
Wall Street analysts forecast CRWV stock price to rise
25 Analyst Rating
12 Buy
13 Hold
0 Sell
Moderate Buy
Current: 97.140
Low
68.00
Averages
123.23
High
180.00
Current: 97.140
Low
68.00
Averages
123.23
High
180.00
About CRWV
CoreWeave, Inc. is a cloud infrastructure technology company. The Company offers the CoreWeave Cloud Platform, which consists of software and cloud services that deliver the automation and efficiency needed to manage complex artificial intelligence (AI) infrastructure. Its CoreWeave Cloud Platform is an integrated solution that is purpose-built for running AI workloads such as model training and inference. Its solutions include infrastructure services, managed software services, and application software services. Its Infrastructure Services provide its customers with access to advanced graphics processing unit (GPU) and central processing unit (CPU) compute, highly performant networking, and storage. Its Managed Software Services include CKS, a flexible virtual private cloud and a bare metal service that runs kubernetes directly on high-performance servers. Its Application Software Services build on top of its infrastructure and managed software services, integrating additional tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Morgan Stanley Takes Cautious Stance on CoreWeave
- Operational Challenges: Morgan Stanley analyst Keith Weiss highlighted that CoreWeave faces operational challenges in a constrained supply environment, with unmet customer demand leading to legal actions from dissatisfied clients, which could harm the company's reputation and market confidence.
- Earnings Expectations: CoreWeave is expected to report approximately $1.53 billion in revenue for Q4 fiscal 2025, with an adjusted loss per share of $0.49, indicating profitability pressures amidst high demand, potentially affecting investor sentiment.
- Expansion Plans: Morgan Stanley noted that CoreWeave needs to expand its active power capacity beyond 850 megawatts and resolve past data center construction delays to achieve sustainable growth and enhance its competitive position in the market.
- Financing Uncertainty: According to a Business Insider report, Blue Owl Capital was unable to secure financing for a proposed data center transaction involving CoreWeave, adding further uncertainty to the company's expansion plans, which may put additional pressure on its stock price.
See More
CoreWeave Faces Class Action Lawsuit Risks
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased CoreWeave securities between March 28 and December 15, 2025, can seek lead plaintiff status by March 13, 2026, indicating significant investor concern over potential fraud.
- Major Pre-IPO Deal: In March 2025, CoreWeave announced a deal worth up to $11.9 billion with OpenAI for AI infrastructure, yet the validity and feasibility of this deal are questioned in the lawsuit, potentially undermining investor confidence.
- Merger Agreement Failure: In October 2025, Core Scientific failed to secure enough shareholder votes to approve its merger with CoreWeave, resulting in a termination of the agreement and a subsequent stock price drop of over 6%, reflecting market apprehension about the company's future.
- Revenue Guidance Downgrade: CoreWeave lowered its revenue guidance in November 2025 due to delays from a third-party data center developer, leading to a further stock price decline of over 16%, highlighting significant operational management challenges facing the company.
See More
CoreWeave Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: CoreWeave, Inc. (NASDAQ: CRWV) is facing a class action lawsuit for securities fraud, involving investors who purchased securities between March 28, 2025, and December 15, 2025, alleging significant misstatements regarding the company's ability to meet customer demand, potentially leading to investor losses.
- Key Allegations: The lawsuit claims that CoreWeave overstated its capacity to meet customer demand and failed to adequately disclose its reliance on a single third-party data center supplier, creating substantial operational and delivery risks that impacted financial expectations.
- Investor Action: Investors are urged to apply to be lead plaintiffs by March 13, 2026, to represent all investors in the litigation, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations and encouraging affected investors to contact attorneys to understand their legal rights.
- Law Firm Overview: Kessler Topaz Meltzer & Check, LLP is a leading U.S. plaintiff-side law firm focused on securities fraud class actions, representing both individual and institutional investors, and has received multiple industry accolades, demonstrating its strong capabilities in securities recovery.
See More
CoreWeave Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against CoreWeave in the U.S. District Court for New Jersey on behalf of investors who purchased securities between March 28, 2025, and December 15, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The lawsuit alleges that CoreWeave's management issued false and misleading statements, failing to disclose the risks associated with reliance on a single third-party data center supplier, which could materially impact the company's revenue.
- Investor Rights Protection: Affected investors have until March 13, 2026, to apply to be appointed as lead plaintiff in the lawsuit, highlighting the importance of investor rights and the transparency of legal proceedings.
- Legal Consultation Available: Bragar Eagel & Squire offers free consultations, allowing investors to contact attorneys via phone or email to learn more about the lawsuit and their legal rights.
See More
CoreWeave Faces Class Action for Securities Fraud Amid Stock Drops
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against CoreWeave and its executives for securities fraud following significant stock drops, with investors encouraged to apply to lead the case by March 13, 2026.
- Stock Price Volatility: CoreWeave's stock fell over 6% on October 30, 2025, from $139.93 to $131.06 after failing to secure enough shareholder votes for its merger with Core Scientific, indicating market disappointment in the merger prospects.
- Earnings Warning: On November 10, 2025, CoreWeave lowered its revenue and operating income guidance due to delays from a third-party data center developer, causing its stock to plummet over 16%, from $105.61 to $88.39, highlighting severe operational shortcomings.
- Construction Delays: The Wall Street Journal reported on December 15, 2025, that delays in a major data center in Texas led to a further stock drop of over 3%, from $72.35 to $69.50, exacerbating investor concerns about CoreWeave's future growth prospects.
See More
Billionaire Laffont Sells CoreWeave Stake, Invests in Moderna
- Portfolio Adjustment: Billionaire Philippe Laffont sold his entire position in CoreWeave during Q4, which represented 2.2% of his portfolio, indicating a significant shift in his investment strategy within the AI sector.
- CoreWeave Performance: Laffont's investment in CoreWeave saw an approximately 80% increase since its IPO, allowing him to lock in substantial gains through this sale, demonstrating his keen market timing.
- New Investment Direction: He also acquired 200,000 shares of Moderna, a position that constitutes only 0.01% of his portfolio, reflecting his ongoing interest in the biotech sector, especially given Moderna's nearly 50% stock price surge recently.
- Long-Term Growth Potential: Moderna is pivoting to introduce a flu vaccine and develop treatments for oncology and rare diseases, which could yield long-term returns for investors if its clinical programs succeed, showcasing Laffont's confidence in future growth opportunities.
See More
Morgan Stanley Takes Cautious Stance on CoreWeave
- Operational Challenges: Morgan Stanley analyst Keith Weiss highlighted that CoreWeave faces operational challenges in a constrained supply environment, with unmet customer demand leading to legal actions from dissatisfied clients, which could harm the company's reputation and market confidence.
- Earnings Expectations: CoreWeave is expected to report approximately $1.53 billion in revenue for Q4 fiscal 2025, with an adjusted loss per share of $0.49, indicating profitability pressures amidst high demand, potentially affecting investor sentiment.
- Expansion Plans: Morgan Stanley noted that CoreWeave needs to expand its active power capacity beyond 850 megawatts and resolve past data center construction delays to achieve sustainable growth and enhance its competitive position in the market.
- Financing Uncertainty: According to a Business Insider report, Blue Owl Capital was unable to secure financing for a proposed data center transaction involving CoreWeave, adding further uncertainty to the company's expansion plans, which may put additional pressure on its stock price.
See More
CoreWeave Faces Class Action Lawsuit Risks
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased CoreWeave securities between March 28 and December 15, 2025, can seek lead plaintiff status by March 13, 2026, indicating significant investor concern over potential fraud.
- Major Pre-IPO Deal: In March 2025, CoreWeave announced a deal worth up to $11.9 billion with OpenAI for AI infrastructure, yet the validity and feasibility of this deal are questioned in the lawsuit, potentially undermining investor confidence.
- Merger Agreement Failure: In October 2025, Core Scientific failed to secure enough shareholder votes to approve its merger with CoreWeave, resulting in a termination of the agreement and a subsequent stock price drop of over 6%, reflecting market apprehension about the company's future.
- Revenue Guidance Downgrade: CoreWeave lowered its revenue guidance in November 2025 due to delays from a third-party data center developer, leading to a further stock price decline of over 16%, highlighting significant operational management challenges facing the company.
See More
CoreWeave Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: CoreWeave, Inc. (NASDAQ: CRWV) is facing a class action lawsuit for securities fraud, involving investors who purchased securities between March 28, 2025, and December 15, 2025, alleging significant misstatements regarding the company's ability to meet customer demand, potentially leading to investor losses.
- Key Allegations: The lawsuit claims that CoreWeave overstated its capacity to meet customer demand and failed to adequately disclose its reliance on a single third-party data center supplier, creating substantial operational and delivery risks that impacted financial expectations.
- Investor Action: Investors are urged to apply to be lead plaintiffs by March 13, 2026, to represent all investors in the litigation, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations and encouraging affected investors to contact attorneys to understand their legal rights.
- Law Firm Overview: Kessler Topaz Meltzer & Check, LLP is a leading U.S. plaintiff-side law firm focused on securities fraud class actions, representing both individual and institutional investors, and has received multiple industry accolades, demonstrating its strong capabilities in securities recovery.
See More
CoreWeave Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against CoreWeave in the U.S. District Court for New Jersey on behalf of investors who purchased securities between March 28, 2025, and December 15, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The lawsuit alleges that CoreWeave's management issued false and misleading statements, failing to disclose the risks associated with reliance on a single third-party data center supplier, which could materially impact the company's revenue.
- Investor Rights Protection: Affected investors have until March 13, 2026, to apply to be appointed as lead plaintiff in the lawsuit, highlighting the importance of investor rights and the transparency of legal proceedings.
- Legal Consultation Available: Bragar Eagel & Squire offers free consultations, allowing investors to contact attorneys via phone or email to learn more about the lawsuit and their legal rights.
See More
CoreWeave Faces Class Action for Securities Fraud Amid Stock Drops
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against CoreWeave and its executives for securities fraud following significant stock drops, with investors encouraged to apply to lead the case by March 13, 2026.
- Stock Price Volatility: CoreWeave's stock fell over 6% on October 30, 2025, from $139.93 to $131.06 after failing to secure enough shareholder votes for its merger with Core Scientific, indicating market disappointment in the merger prospects.
- Earnings Warning: On November 10, 2025, CoreWeave lowered its revenue and operating income guidance due to delays from a third-party data center developer, causing its stock to plummet over 16%, from $105.61 to $88.39, highlighting severe operational shortcomings.
- Construction Delays: The Wall Street Journal reported on December 15, 2025, that delays in a major data center in Texas led to a further stock drop of over 3%, from $72.35 to $69.50, exacerbating investor concerns about CoreWeave's future growth prospects.
See More
Billionaire Laffont Sells CoreWeave Stake, Invests in Moderna
- Portfolio Adjustment: Billionaire Philippe Laffont sold his entire position in CoreWeave during Q4, which represented 2.2% of his portfolio, indicating a significant shift in his investment strategy within the AI sector.
- CoreWeave Performance: Laffont's investment in CoreWeave saw an approximately 80% increase since its IPO, allowing him to lock in substantial gains through this sale, demonstrating his keen market timing.
- New Investment Direction: He also acquired 200,000 shares of Moderna, a position that constitutes only 0.01% of his portfolio, reflecting his ongoing interest in the biotech sector, especially given Moderna's nearly 50% stock price surge recently.
- Long-Term Growth Potential: Moderna is pivoting to introduce a flu vaccine and develop treatments for oncology and rare diseases, which could yield long-term returns for investors if its clinical programs succeed, showcasing Laffont's confidence in future growth opportunities.
See More
